Table 1.
Chemosensitivity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay
| Drug | EC50 | PPC |
|---|---|---|
| |
(μg/mL) |
(μg/mL) |
| ACD |
>0.1 |
0.08 |
| ADM |
16.5 |
0.4 |
| BLM |
>1000 |
3.3 |
| CBDCA |
>300 |
37.1 |
| CDDP |
23.2 |
8.5 |
| CPA |
>10 |
4.3 |
| CPT-11 |
1.79 |
0.05 |
| 5-FU |
497 |
15.3 |
| MMC |
6.5 |
2.4 |
| MTX |
>300 |
3 |
| PTX |
5.1 |
11.8 |
| VCR |
15 |
0.1 |
| VLB |
16 |
0.15 |
| VP-16 | 197 | 13 |
EC50, effective concentration for 50% kill; PPC, peak plasma concentration taken intravenously; ACD, actinomycin D; ADM, doxorubicin; BLM, bleomycin; CBDCA, carboplatin; CDDP, cisplatin; CPA, 4-hydroperoxy-cyclophosphamide; CPT-11, irinotecan hydrochloride; 5-FU, 5-fluorouracil; MMC, mitomycin C; MTX, methotrexate; PTX, paclitaxel; VCR, vincristine; VLB, vinblastine; VP-16, etoposide;.